• Thurs news: Novartis not joining weight loss race. Pharma marketing and climate change. Roche flu treatment trial. Cercle’s fund raise for women’s health. ICER looks at GSK COPD drugs. See more on our front page

ASH: Roche bispecific delivers for hard-to-treat lymphoma patients failed by CAR-Ts

cafead

Administrator
Staff member
  • cafead   Dec 09, 2019 at 09:52: AM
via Roche has rolled out new data showing mosunetuzumab can trigger complete responses in a tough group—lymphoma patients failed by CAR-Ts and other drugs. The phase 1/2b linked the bispecific antibody to long-lasting responses in a significant minority of hard-to-treat non-Hodgkin lymphoma patients.

article source
 

<